![]() |
Name |
Neosolaniol 8-isobutyrate
|
Molecular Formula | C23H32O9 | |
IUPAC Name* |
[(1S,2R,4S,7R,9R,10R,11S,12S)-11-acetyloxy-2-(acetyloxymethyl)-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-4-yl] 2-methylpropanoate
|
|
SMILES |
CC1=C[C@@H]2[C@](C[C@@H]1OC(=O)C(C)C)([C@]3([C@@H]([C@H]([C@H]([C@@]34CO4)O2)O)OC(=O)C)C)COC(=O)C
|
|
InChI |
InChI=1S/C23H32O9/c1-11(2)20(27)31-15-8-22(9-28-13(4)24)16(7-12(15)3)32-19-17(26)18(30-14(5)25)21(22,6)23(19)10-29-23/h7,11,15-19,26H,8-10H2,1-6H3/t15-,16+,17+,18+,19+,21+,22+,23-/m0/s1
|
|
InChIKey |
CZZOBJORBLRBLT-DSCHAYMESA-N
|
|
Synonyms |
8-Isobutyrylneosolaniol; Neosolaniol 8-isobutyrate; 8-Isobutanoylneosolaniol; 7OCL55CN56; 111112-48-2; UNII-7OCL55CN56; CHEBI:175609; [(1S,2R,4S,7R,9R,10R,11S,12S)-11-acetyloxy-2-(acetyloxymethyl)-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-4-yl] 2-methylpropanoate; TRICHOTHEC-9-ENE-3,4,8,15-TETROL, 12,13-EPOXY-, 4,15-DIACETATE 8-(2-METHYLPROPANOATE), (3.ALPHA.,4.BETA.,8.ALPHA.)-; Trichothec-9-ene-3,4,8,15-tetrol, 12,13-epoxy-, 4,15-diacetate 8-(2-methylpropanoate), (3alpha,4beta,8alpha)-
|
|
CAS | 111112-48-2 | |
PubChem CID | 91809166 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 452.5 | ALogp: | 0.7 |
HBD: | 1 | HBA: | 9 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 121.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 32 | QED Weighted: | 0.288 |
Caco-2 Permeability: | -5.334 | MDCK Permeability: | 0.00006960 |
Pgp-inhibitor: | 0.799 | Pgp-substrate: | 0.996 |
Human Intestinal Absorption (HIA): | 0.048 | 20% Bioavailability (F20%): | 0.694 |
30% Bioavailability (F30%): | 0.924 |
Blood-Brain-Barrier Penetration (BBB): | 0.393 | Plasma Protein Binding (PPB): | 35.08% |
Volume Distribution (VD): | 1.346 | Fu: | 45.84% |
CYP1A2-inhibitor: | 0.027 | CYP1A2-substrate: | 0.112 |
CYP2C19-inhibitor: | 0.036 | CYP2C19-substrate: | 0.608 |
CYP2C9-inhibitor: | 0.02 | CYP2C9-substrate: | 0.02 |
CYP2D6-inhibitor: | 0.025 | CYP2D6-substrate: | 0.093 |
CYP3A4-inhibitor: | 0.564 | CYP3A4-substrate: | 0.448 |
Clearance (CL): | 3.085 | Half-life (T1/2): | 0.604 |
hERG Blockers: | 0.077 | Human Hepatotoxicity (H-HT): | 0.728 |
Drug-inuced Liver Injury (DILI): | 0.889 | AMES Toxicity: | 0.93 |
Rat Oral Acute Toxicity: | 0.247 | Maximum Recommended Daily Dose: | 0.039 |
Skin Sensitization: | 0.424 | Carcinogencity: | 0.089 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.024 |
Respiratory Toxicity: | 0.474 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001179 | ![]() |
0.860 | D0G7KJ | ![]() |
0.281 | ||
ENC002259 | ![]() |
0.854 | D09SIK | ![]() |
0.270 | ||
ENC003278 | ![]() |
0.826 | D0OL7F | ![]() |
0.270 | ||
ENC003580 | ![]() |
0.776 | D0L2UN | ![]() |
0.265 | ||
ENC003086 | ![]() |
0.725 | D08BDT | ![]() |
0.262 | ||
ENC005517 | ![]() |
0.697 | D0H2MO | ![]() |
0.259 | ||
ENC005516 | ![]() |
0.676 | D09WYX | ![]() |
0.254 | ||
ENC005586 | ![]() |
0.602 | D03ZZK | ![]() |
0.252 | ||
ENC005587 | ![]() |
0.407 | D0K7HU | ![]() |
0.252 | ||
ENC005782 | ![]() |
0.319 | D0X7XG | ![]() |
0.243 |